SMMT - Summit Therapeutics plc
| Previous Close | 2.2500 |
| Open | 2.2500 |
| Bid | 2.0300 x 1000 |
| Ask | 2.1100 x 900 |
| Day's Range | 1.9500 - 2.2500 |
| 52 Week Range | 1.9500 - 16.8610 |
| Volume | 135,328 |
| Avg. Volume | 151,401 |
| Market Cap | 34.585M |
| Beta | 0.94 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7700 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.86 |
- GlobeNewswire•9 days ago
Summit Therapeutics to Present at the Canaccord Genuity Growth Conference
OXFORD, United Kingdom and CAMBRIDGE, Mass., Aug. 06, 2018-- Summit Therapeutics plc announces that Glyn Edwards, Chief Executive Officer, will present at the Canaccord Genuity Growth Conference on 9 August ...
- GlobeNewswire•13 days ago
Phase 2 Clinical Data Published Showing Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile Infection
Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces today the publication in the journal PLOS ONE of microbiome analyses highlighting ridinilazole as a precision antibiotic in development for the treatment of C. difficile infection (‘CDI’). The clinical management of CDI is stymied by poor sustained cures due to high recurrence rates after initial infection. In a double-blind Phase 2 clinical trial, ridinilazole was highly preserving of patients’ microbiomes compared to patients treated with the broad-spectrum standard of care antibiotic vancomycin.
- PR Newswire•16 days ago
Summit Therapeutics Joins Antimicrobials Working Group
WASHINGTON , July 30, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Summit Therapeutics plc (NASDAQ: SMMT; AIM: SUMM) (Summit) to its coalition of companies ...
- American City Business Journals•last month
Cambridge biotech Summit pivots from failed trial, layoffs with $4.5M from CARB-X
CARB-X's $4.5 million award comes just a few weeks after the company shut down on a Duchenne muscular dystrophy trial and laid off most of their employees in Cambridge.
- GlobeNewswire•last month
Summit Awarded up to $4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics
Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces it has been awarded up to $4.5 million from CARB-X, a public-private partnership devoted to accelerating early antibiotic research and development. This award will be used to support Summit’s wholly-owned, lead series of new mechanism antibiotic compounds for gonorrhoea. Gonorrhoea is recognised as an urgent bacterial threat by the US Centers for Disease Control (‘CDC’) due to the diminishing treatment arsenal.
- Zacks•last month
Summit Therapeutics Enters Oversold Territory
Summit Therapeutics Enters Oversold Territory
- ACCESSWIRE•2 months ago
Today’s Research Reports on Stocks to Watch: Aquinox Pharmaceuticals and Summit Therapeutics
NEW YORK, NY / ACCESSWIRE / June 28, 2018 / Aquinox Pharmaceuticals and Summit Therapeutics both saw their shares dramatically drop on Wednesday after each company announced failed trial results. Aquinox Pharmaceuticals, Inc. shares closed down almost 85% on Wednesday and hit a new low of $2.25 on about 14.2 million shares traded. The company revealed that late-stage trial results for its bladder pain drug failed to perform better than the placebo in patients.
- GlobeNewswire•2 months ago
Summit Announces PhaseOut DMD Did Not Meet Primary Endpoint
Summit Therapeutics plc (SUMM.L) (SMMT) today announces PhaseOut DMD has not met its primary or secondary endpoints after 48 weeks of treatment of ezutromid in patients with Duchenne muscular dystrophy (‘DMD’). PhaseOut DMD was a multi-centre, open-label Phase 2 clinical trial of the utrophin modulator, ezutromid. Based on this outcome, the Company is discontinuing its development of ezutromid and as a result, will be implementing cost reduction measures.
- GlobeNewswire•2 months ago
Summit Therapeutics to Present at the JMP Securities Life Sciences Conference
Oxford, June 15, 2018-- Oxford, UK, and Cambridge, MA, US, 15 June 2018– Summit Therapeutics plc announces that Glyn Edwards, Chief Executive Officer, will present at the JMP Securities Life Sciences Conference ...
- GlobeNewswire•2 months ago
Summit Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018
Summit Therapeutics plc (SMMT) (SUMM.L) announces the discovery of a second novel target to kill the bacteria Neisseria gonorrhoeae. The new target, identified using Summit’s Discuva Platform, is distinct from that of existing antibiotics and also from Summit’s recently announced lead series of new mechanism antibiotics for gonorrhoea. Summit also reports the discovery of a promising new series of compounds against this second target.
- GlobeNewswire•2 months ago
Consolidated Research: 2018 Summary Expectations for Summit Therapeutics, Orbotech, Amphastar Pharmaceuticals, Mizuho Financial Group, Endo International plc, and AXT — Fundamental Analysis, Key Performance Indications
NEW YORK, June 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Summit ...
- GlobeNewswire•2 months ago
Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2018 and Operational Progress
OXFORD, United Kingdom and CAMBRIDGE, Mass., June 05, 2018-- Summit Therapeutics plc today reports its financial results for the first quarter ended 30 April 2018 and provides an update on operational ...
- GlobeNewswire•2 months ago
Summit Therapeutics Provides Notice of Financial Results for the First Quarter Ended 30 April 2018
OXFORD, United Kingdom and CAMBRIDGE, Mass., June 01, 2018-- Summit Therapeutics plc will announce its financial results for the first quarter ended 30 April 2018 on 5 June 2018.. About Summit Therapeutics ...
